TLE4 regulation of wnt-mediated inflammation underlies its role as a tumor suppressor in myeloid leukemia
- PMID: 27486062
- PMCID: PMC5266616
- DOI: 10.1016/j.leukres.2016.07.002
TLE4 regulation of wnt-mediated inflammation underlies its role as a tumor suppressor in myeloid leukemia
Abstract
The presence of AML1-ETO (RUNX1-CBF2T1), a fusion oncoprotein resulting from a t(8;21) chromosomal translocation, has been implicated as a necessary but insufficient event in the development of a subset of acute myeloid leukemias (AML). While AML1-ETO prolongs survival and inhibits differentiation of hematopoietic stem cells (HSC), other contributory events are needed for cell proliferation and leukemogenesis. We have postulated that specific tumor suppressor genes keep the leukemic potential of AML1-ETO in check. In studying del(9q), one of the most common concomitant chromosomal abnormalities with t(8;21), we identified the loss of an apparent tumor suppressor, TLE4, that appears to cooperate with AML1-ETO to confer a leukemic phenotype. This study sought to identify the molecular basis of this cooperation. We show that the loss of TLE4 confers proliferative advantage to leukemic cells, simultaneous with an upregulation of a pro- inflammatory signature mediated through aberrant increases in Wnt signaling activity. We further demonstrate that inhibition of cyclooxygenase (COX) activity partly reverses the pro-leukemic phenotype due to TLE4 knockdown, pointing towards a novel therapeutic approach for myeloid leukemia.
Keywords: AML1-ETO; Acute myeloid leukemia; Inflammation; TLE4; Tumor suppressor; Wnt signaling.
Copyright © 2016 Elsevier Ltd. All rights reserved.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures











Similar articles
-
Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperates with AML1-ETO to affect myeloid cell proliferation and survival.Blood. 2008 Apr 15;111(8):4338-47. doi: 10.1182/blood-2007-07-103291. Epub 2008 Feb 7. Blood. 2008. PMID: 18258796 Free PMC article.
-
Delineation of the minimal commonly deleted segment and identification of candidate tumor-suppressor genes in del(9q) acute myeloid leukemia.Genes Chromosomes Cancer. 2005 Nov;44(3):279-91. doi: 10.1002/gcc.20236. Genes Chromosomes Cancer. 2005. PMID: 16015647
-
The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.Nat Med. 2002 Jul;8(7):743-50. doi: 10.1038/nm726. Epub 2002 Jun 24. Nat Med. 2002. PMID: 12091906
-
The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.Haematologica. 1997 May-Jun;82(3):364-70. Haematologica. 1997. PMID: 9234595 Review.
-
The t(8;21) fusion protein contacts co-repressors and histone deacetylases to repress the transcription of the p14ARF tumor suppressor.Blood Cells Mol Dis. 2003 Mar-Apr;30(2):177-83. doi: 10.1016/s1079-9796(03)00021-4. Blood Cells Mol Dis. 2003. PMID: 12732181 Review.
Cited by
-
Evolution from adherent to suspension: systems biology of HEK293 cell line development.Sci Rep. 2020 Nov 4;10(1):18996. doi: 10.1038/s41598-020-76137-8. Sci Rep. 2020. PMID: 33149219 Free PMC article.
-
ATIQCTPC targeting MMP-9: a key step to slowing primary tumor growth and inhibiting metastasis of lewis lung carcinoma in vivo.Oncotarget. 2017 Jul 10;8(38):63881-63889. doi: 10.18632/oncotarget.19172. eCollection 2017 Sep 8. Oncotarget. 2017. PMID: 28969037 Free PMC article.
-
Roles of transducin-like enhancer of split (TLE) family proteins in tumorigenesis and immune regulation.Front Cell Dev Biol. 2022 Nov 11;10:1010639. doi: 10.3389/fcell.2022.1010639. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 36438567 Free PMC article. Review.
-
Bioinformatics and Experimental Validation for Identifying Biomarkers Associated with AMG510 (Sotorasib) Resistance in KRASG12C-Mutated Lung Adenocarcinoma.Int J Mol Sci. 2024 Jan 26;25(3):1555. doi: 10.3390/ijms25031555. Int J Mol Sci. 2024. PMID: 38338834 Free PMC article.
-
Unique, Intersecting, and Overlapping Roles of C/EBP β and CREB in Cells of the Innate Immune System.Sci Rep. 2018 Nov 16;8(1):16931. doi: 10.1038/s41598-018-35184-y. Sci Rep. 2018. PMID: 30446701 Free PMC article.
References
-
- American Cancer Society. Cancer facts & figures. Annu Rep. 2013
-
- Kusec R, Laczika K, Knöbl P, Friedl J, Greinix H, Kahls P, et al. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia. 1994;8:735–739. - PubMed
-
- Jurlander J, Caligiuri MA, Ruutu T, Baer MR, Strout MP, Oberkircher AR, et al. Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood. 1996;88:2183–2191. - PubMed
-
- Wiemels JL, Xiao Z, Buffler PA, Maia AT, Ma X, Dicks BM, et al. In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. Blood. 2002;99:3801–3805. - PubMed
-
- Nimer SD, Moore MA. Effects of the leukemia-associated AML1-ETO protein on hematopoietic stem and progenitor cells. Oncogene. 2004;23:4249–4254. http://dx.doi.org/10.1038/sj.onc.1207673. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases